The expression of GOT1 was up-regulated in pancreatic ductal adenocarcinoma (PDAC) (9–11), colorectal cancer (12, 13), breast cancer (14–16), lung adenocarcinoma (17), glioblastoma (17), prostate cancer (17–19), acute myeloid leukemia (20), and multiple myeloma (21), while down-regulated in poorly-differentiated hepatocellular carcinoma cells (22). This evidence concerns the gene GOT1 and hepatocellular carcinoma.